Research programme: designed repeat proteins - Molecular Partners/Janssen
Alternative Names: MP 0210; MP 0270Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Molecular Partners AG
- Developer Janssen Biotech; Molecular Partners AG
- Class Proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Immunological disorders; Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in Switzerland
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Immunological-disorders in USA